#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Hyperuricemia and cardiovascular diseases

Czech version

Authors: Andrej Dukát
Authors‘ workplace: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava
Published in: Forum Diab 2019; 8(1): 21-25
Category: Review Article

Overview

For already longer period of time it was suggested, that there is a potential relationship of increased acid uric to many clinical states in internal medicine. However only during last two decades important association also to cardiovascular diseases is now confirmed. At present we have enough of data, that increase of acid uric level represents an useful biomarker, which enables the clinician to evaluate the patient´s risk and also to start preventive approach.

Keywords:

hyperuricemia – cardiovascular diseases – prevention – treatment

Sources
  1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359(17): 1811–1821. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0800885>. Erratum in N Engl J Med 2010; 362(23): 2235.
  2. Whelton A. Hyperuricemia and hypertension. A Confluence of Concepts. Editorial Commentary. Hypertension 2012; 60(5): 1112–1113. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.198341>.
  3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63(10): 3136–3141. Dostupné z DOI: <http://dx.doi.org/10.1002/art.30520>.
  4. Loeffler LF, Navas-Acien A, Brady TM et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension 2012; 59(4): 811–817. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.183244>.
  5. Culleton BF, Larson MG, Kannel WB et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131(1): 7–13.
  6. Feig DI, Johnson RJ. Hyperuricaemia in childhood primary hypertension. Hypertension 2003; 42(3): 247–252. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000085858.66548.59>.
  7. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300(8): 924–932. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.300.8.924>.
  8. [National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents]. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114(2 Suppl 4th Report): 555–576.
  9. Khosla UM, Zharikov S, Finch JL et al. Hyperuricaemia induces endothelial dysfunction. Kidney Int 2005; 67(5): 1739–1742. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1523–1755.2005.00273.x>.
  10. Price KL, Sautin YY, Long DA et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006; 17(17): 1791–1795. Dostupné z DOI: <http://dx.doi.org/10.1681/ASN.2006030264>.
  11. Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, cul-prits and circles. Am J Kidney Dis 2010; 56(2): 247–250. <http://dx.doi.org/10.1053/j.ajkd.2010.06.004>.
  12. Kang DH, Nakagawa T, Feng L et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13(12): 2888–2897.
  13. Masuo K, Kawaguchi H, Mikami H at al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42(4): 474–480. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000091371.53502.D3>.
  14. Bošmanský K, Pullmann R. Dna. In: Ďuriš I, Hulin I, Bernadič M. Princípy internej medicíny. SAP: Bratislava 2001;1534–1548. ISBN 8088908698.
  15. Špinar J, Vítovec J, Pařenica J. Hypertenze a hyperurikemie. Vnitř Lék 2005; 51(1): 82–86.
  16. Ghei M, Mihailescu M, Levinson J et al. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rev 2002; 4(3): 270–274.
  17. Keenan S. Relation of Uric Acid to Serum Levels of High-Sensitivity CRP, Triglycerides, and HDL-C and to Hepatic Steatosis. Am J Cardiol 2012; 110(12): 1787–1792. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2012.08.012>.
  18. Alderman MH. Podagra, Urid Acid and Cardiovascular Disease. Circulation 2007; 116(8): 880–883. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.728600>.
  19. Choi HK, Curhan G. Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease. Circulation 2007; 116(8): 894–900. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.703389>.
  20. Dukát A, Gajdošík J, Kriška M et al. Predstavuje dnes kyselina močová marker rizika srdcovocievnych ochorení? Rev Med 2015; 13(1): 10–13.
  21. Pavelka K. Nové pohledy na léčbu hyperurikémie a dny. Interní Med 2008; 10(6): 268–272.
  22. Canpolat C. Usefulness of Preprocedural Serum Uric Acid Level to Predict Restenosis of Bare Metal Stents. Am J Cardiol 2014; 113(2): 197–202. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2013.09.004>.
  23. White WB, Saag KG, Becker MA et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018; 378(13): 1200–1210. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1710895>.
  24. Choi HK, Soriano LC, Zhang Y et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190. Dostupné z DOI: <https://doi.org/10.1136/bmj.d8190>.
  25. Mackenzie I, Ford I, Hawkey C et al. [ALL-HEART study group]. AB1029 Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART) study: baseline characteristics of the randomised patient population. Ann Rheum Dis 2018; 77(Suppl 2): 1631. Dostupné z DOI: <http://doi 10.1136/annrheumdis-2018-eular.6734>.
  26. Marchioli R, Valagussa F. The results of the GISSI-Preventione trial in the general framework of secondary prevention. Eur Heart J 2000; 21(12): 949–952.
Labels
Diabetology Endocrinology Internal medicine
Uric acid: pathophysiological implications
Hyperuricemia and diabetes mellitus
Hyperuricemia and kidney
Gout as a new old problem faced by an outpatient care physician
Treatment of hyperuricemia
Treat to target in gouty arthritis
Article was published in

Forum Diabetologicum

Issue 1
2019 Issue 1
Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#